SecBot SecBot
8-K ·Filed Sep 14, 2026

ARMP

Armata Pharmaceuticals, Inc.
BULLISH
Impact 7/10
Horizonweeks Processed2mo ago SEC0001104659-26-107253
8-K context-dependent: Items 7.01
Actionable Insight ▲ Bullish

This Breakthrough Therapy designation is a major derisking event for AP-SA02, providing expedited FDA review and enhanced regulatory engagement. The strong Phase 2 efficacy data (100% vs 75% clinical response) supports a superiority claim in Phase 3. Monitor for Phase 3 initiation in H2 2026 and any partnership or financing announcements given the company's pre-revenue status.

DirectionBullish
Confidencehigh
Horizonweeks

AP-SA02

◆ Mixed Named in this 8-K
Impact
Phase
Phase 2 complete; Phase 3 (registrational) planned for H2 2026
Time to market
Phase 3 (registrational) initiation expected H2 2026; pivotal data and any BLA/approval are realistically 2028-2030 at the earliest, contingent on Phase 3 success — AP-SA02 is years from commercialization.
Next catalyst
None dated

What to watchWatch for confirmation of the Phase 3 start (H2 2026 window) and any financing announcement, because the ~$5.07 stock's biggest near-term risks are cash runway and dilution, not trial mechanics. The real share-price binary, Phase 3 topline data, is likely 2+ years out, so treat the gap between the stock and the ~$17.5 mean analyst target as a long-dated optionality play, not a near-term event.

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$5.55
T+0 close · Sep 14, 2026 · via day close
Latest settled
−34.59%
T+20 · $3.63 · next T+60 in 21d
Vs SPY
−36.86%
α at T+20
Latest observation
−16.20%
T+44 · FF3 residual α
  1. T+0 · Sep 14 $5.55entry
  2. T+1 · 2mo ago −20.72%α −20.26% · $4.40
  3. T+5 · 8w ago −23.24%α −23.35% · $4.26
  4. T+20 · 5w ago −34.59%α −36.86% · $3.63
  5. T+45 · todayOpen
  6. T+60 · in 21d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Armata Pharmaceuticals announced FDA Breakthrough Therapy designation for AP-SA02, its intravenous phage therapy for complicated Staphylococcus aureus bacteremia (including MRSA). The designation is supported by Phase 1b/2a data showing 100% of AP-SA02 patients maintained clinical response at 28 days vs. 75% for placebo, and provides expedited FDA review, cross-disciplinary collaboration, and senior management engagement. This is a significant regulatory milestone that de-risks the Phase 3 program and enhances the asset's value, though the company remains pre-revenue with no financial data in this filing.

Key Facts

  • FDA granted Breakthrough Therapy designation to AP-SA02 for adjunct treatment of complicated S. aureus bacteremia (MSSA and MRSA)
  • Phase 1b/2a diSArm study: 100% of AP-SA02 patients maintained clinical response at 28 days vs. 75% for placebo
  • AP-SA02 now holds Breakthrough Therapy, Fast Track, and QIDP designations
  • Phase 3 superiority study anticipated to initiate in second half of 2026
  • Development partially supported by a $28.7 million Department of War award

Financial Impact

No financial data in filing; Phase 3 costs partially funded by $28.7M DoW award; Breakthrough Therapy designation may accelerate path to market and reduce development risk

Risk Factors

  • Phase 3 trial may fail to replicate Phase 2 results
  • Company is pre-revenue and will require additional capital to complete Phase 3 and commercialization
  • Bacteriophage therapy is a novel modality with regulatory and manufacturing uncertainties

Market Snapshot

Exchange
NYSE
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-107253
Document: tm2625289d1_ex99-1.htm0001104659-26-107253
Document: 0001104659-26-107253-index-headers.html0001104659-26-107253
Document: 0001104659-26-107253-index.html0001104659-26-107253
Document: 0001104659-26-107253.txt0001104659-26-107253

Track record

6 reports on ARMP

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +43.90% at T+60 after the May 13, 2026 report. 3 of 3 went positive at some point.

Filters
  1. Nov 12, 20264d ago Press Release Neutral 5/10 Entry $3.87 Now $2.99 −22.74% settles Dec 14
  2. Sep 23, 20267w ago 8-K Bullish 5/10 Entry $3.64 to $3.06 Now $2.99 −17.86% ▼ −15.93% −16.62% vs SPY
  3. Sep 14, 20269w ago 8-K Bullish 7/10 Viewing Entry $5.55 to $3.63 Now $2.99 −46.13% ▼ −34.59% −36.86% vs SPY
  4. Jul 20, 202617w ago 8-K Bullish 5/10 Entry $5.06 to $4.48 Now $2.99 −40.91% ▼ −11.46% −15.58% vs SPY
  5. May 13, 202626w ago 8-K Bearish 6/10 Entry $8.20 to $7.58 Now $2.99 +63.54% ▲ +7.56% +6.70% vs SPY
  6. Apr 27, 202629w ago 8-K Neutral 3/10 Entry $11.00 to $8.17 Now $2.99 −72.82% ▼ −25.73% −30.68% vs SPY
Showing 6 of 6

US Market Status

Market Closed · Opens Wed (10h 5m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 14, 2026